Landscape Surrounding HER2 ADCs in GI Cancers
Martin Dietrich, MD, PhD, discusses the role of HER2 ADCs in GI cancers, reviewing key data from DESTINY-Gastric and DESTINY-CRC trials.
Stay updated with breaking news from Solid Tumors. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Martin Dietrich, MD, PhD, discusses the role of HER2 ADCs in GI cancers, reviewing key data from DESTINY-Gastric and DESTINY-CRC trials.
Johnson & Johnson announced today that new clinical and real-world data will be presented via 18 abstracts at the ASCO GU symposium being held January 25-27 in San Francisco, underlining the company's...
Onward Therapeutics SA (Onward Therapeutics), a global biotechnology company focused on developing innovative immunotherapies for cancer treatment, today announced that the phase 1 clinical trial of OT-A201 (Study No. A20101), a first-in-class bispecific antibody targeting two immune checkpoints is in progress.
/PRNewswire/ -- Johnson & Johnson announced today new clinical and real-world evidence data will be featured in 18 abstracts at this year's ASCO GU Symposium...
By Karen E. Roman Sirnaomics Ltd., a biopharmaceutical company developing RNAi therapeutics, recently published a research article showing a cancer drug candidate to treat solid tumors. The article focused on the company’s clinical studies with STP707, a polypeptide nanoparticle formulation, and provided a foundation for further research to treat hepatocellular carcinoma and other solid tumors, […]